The kynurenine pathway in neurodegenerative diseases: Mechanistic and therapeutic considerations

  title={The kynurenine pathway in neurodegenerative diseases: Mechanistic and therapeutic considerations},
  author={Lin Tan and Jin-Tai Yu and Lan Tan},
  journal={Journal of the Neurological Sciences},

Figures and Tables from this paper

Kynurenine Pathway Metabolites as Biomarkers in Alzheimer's Disease
This review focused on the KP metabolites through the relationship of neuroinflammation in AD, significant KP metabolites, and associated molecular mechanisms as well as the utility of these metabolites as biomarkers and therapeutic targets for patients with AD.
Brain Aging and Disorders of the Central Nervous System: Kynurenines and Drug Metabolism.
This review highlights the alterations in this metabolic pathway in the physiological aging process and in different disorders, which can be achieved through the use of synthetic kynurenic acid analogues, enzyme inhibitors or even nanotechnology.
The Kynurenine Pathway and Kynurenine 3-Monooxygenase Inhibitors
The purpose of this review is to describe the kynurenine pathway, the klynurenine 3-monooxygenase enzyme, and KMO inhibitors and their potential candidacy for clinical use.
The Kynurenine Pathway in Stem Cell Biology
Evidence showing that the kynurenine pathway influences stem cell biology and impacts the functional behavior of progenitor cells is considered.
Neuronal proteins as targets of 3-hydroxykynurenine: Implications in neurodegenerative diseases.
The results open the perspective to using the 3OHKyn-protein/peptide synthetic conjugates to explore their competence to activate microglia cell cultures as well as to unravel their role in neuroinflammatory conditions.
Role of the Kynurenine Pathway in Stem Cell Biology
This chapter considers the current understanding of the role of the KP in stem cell biology and impacts on the functional behaviour of progenitor cells.
Antioxidant Properties of Kynurenines: Density Functional Theory Calculations
The high free radical scavenging activity of 3HAA and 3HOK can be explained by the easiness of H-atom abstraction and transfer to O-atom of the free radical, rather than by Met-OO* addition to the kynurenine radical.


Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies.
It seems hopeful to use kynurenine derivatives or enzyme inhibitors to ensure an increased kynurenic acid concentration in the central nervous system to exert its neuroprotective effects binding at the excitatory glutamate receptors, in particular the NMDA receptors.
Kynurenine and its metabolites in Alzheimer's disease patients.
Examination of peripheral KP in patients with Alzheimer type dementia proves activation of peripheral kynurenine pathway in this type of dementia and offers Novel therapeutic opportunities, with the development of new compounds as a promising perspective for brain neuroprotection.
Targeting the kynurenine pathway as a potential strategy to prevent and treat Alzheimer's disease.
Targeting kynurenine 3-monooxygenase (KMO): implications for therapy in Huntington's disease.
The enzyme kynurenine 3-monooxygenase (KMO) is located at a critical branching point in the KP such that inhibition of this enzyme by either pharmacological or genetic means shifts the flux in the pathway towards the formation of KYNA.
Implications for the Kynurenine Pathway and Quinolinic Acid in Amyotrophic Lateral Sclerosis
The kynurenine pathway is a major route of L-tryptophan catabolism leading to production of several neurobiologically active molecules and most of the factors associated with QUIN toxicity are found in ALS, implying that QUIN may play a substantial role in the neuropathogenesis of ALS.
Targeting the kynurenine pathway-related alterations in Alzheimer's disease: a future therapeutic strategy.
There is a great need for new strategies to improve efficacy, transport across the blood-brain barrier and bioavailability, naturally with simultaneous minimization of the adverse side-effects.
The role of kynurenines in disorders of the central nervous system: Possibilities for neuroprotection
The Involvement of Neuroinflammation and Kynurenine Pathway in Parkinson's Disease
It is likely that pharmacological modulation of the KP will represent a new therapeutic strategy for PD, and previous studies have shown that NMDA antagonists can ease symptoms and exert a neuroprotective effect in PD both in vivo and in vitro.